ADT+Docetaxel+Enzalutamide

Phase 2Small molecule

WWake Forest University Health Sciences

ADT+Docetaxel+Enzalutamide is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 2

Acetylsalicylic Acid

Bayer

Phase 3

2 3

GM-CSF

YY-mAbs Therapeutics

Phase 3

8 4

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 5

Trexall

Jazz Pharmaceuticals

Preclinical

—6

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 7

Duragesic

CCephalon

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Prostate Cancer

NCT03246347

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer

Active, not recruiting·WWake Forest University Health Sciences·Phase 2·NCT03246347·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ADT+Docetaxel+Enzalutamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADT+Docetaxel+Enzalutamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADT+Docetaxel+Enzalutamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWake Forest University Health Sciences

ADT+Docetaxel+Enzalutamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News